Results 111 to 120 of about 1,122,034 (342)
ABSTRACT Introduction Refractory neurogenic lower urinary tract dysfunction presents an obstinate clinical problem. For patients who fail nonsurgical measures, we advocate for bladder‐sparing, continent urinary diversion as the optimal approach to management.
Brian W. Chao, Sean P. Elliott
wiley +1 more source
Urinary Catheterization Induces Delirium-Like Behavior Through Glucose Metabolism Impairment in Mice. [PDF]
Jiang Z +7 more
europepmc +1 more source
ABSTRACT Aims To evaluate the prevalence, clinical course, and risk factors of lower urinary tract symptoms (LUTS) in patients hospitalized with COVID‐19, and to assess associations with comorbidities, disease severity, and vaccination status. Methods We conducted a prospective cohort study of adult patients hospitalized with confirmed COVID‐19, who ...
Julia Duarte de Souza +12 more
wiley +1 more source
Knowledge, skills, and confidence among healthcare staff in urinary catheterization. [PDF]
Bhatt NR +4 more
europepmc +1 more source
A single-center, prospective, randomized clinical trial to investigate the optimal removal time of the urinary catheter after laparoscopic anterior resection of the rectum: study protocol for a randomized controlled trial [PDF]
Lai Xu +8 more
openalex +1 more source
“What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD”—Pro Botox
ABSTRACT Objectives Neurogenic lower urinary tract dysfunction (NLUTD) severely impairs patient quality of life (QoL). While oral medications are often first‐line treatments, their high failure rates and side effects limit their effectiveness. Thus, we argue for the use of intravesical botulinum toxin A (BoNT‐A) injections as a first‐line alternative ...
Vada Furlan +2 more
wiley +1 more source
ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang +2 more
wiley +1 more source

